IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Pharmaceuticals: DSM Joint Venture Percivia Ceases Inhouse Activities

2:53 AM MDT | April 26, 2012 | Alex Scott

DSM and Crucell (Leiden, the Netherlands), a biotech firm, have pulled the plug on all inhouse projects at their biosimilar drugs joint venture company Percivia (Cambridge, MA). Set up in 2007, “Percivia will remain as an entity to serve existing licensees,” DSM tells CW. DSM says that an undisclosed number of staff will be made redundant as a result of the jv’s change of strategy.   Percivia’s business has been based on the use of Crucell’s PER.C6 engineered human cell line that has been specifically developed for industrial...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa